The collaboration aims to integrate AI with digital pathology tools, for speed and accuracy of NSCLC diagnostics. Credit: PeopleImages.com – Yuri A / Shutterstock.

Sheba Medical Center’s innovation arm, Accelerate, Redesign, and Collaborate (ARC), has partnered with Roche to advance the diagnosis and treatment of non-small cell lung cancer (NSCLC) by leveraging AI.

This collaboration aims to integrate AI with digital pathology tools to enhance the speed and accuracy of NSCLC diagnostics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Formalised at the 2024 ARC Summit, the partnership will see the co-development of digital pathology solutions on Roche’s navify Digital Pathology platform.

The goal is to improve the detection of molecular markers in NSCLC, which is expected to lead to faster and more precise detection of patients suitable for targeted treatments and immunotherapies.

This solution significantly minimises the time from diagnosis to treatment and could save lives, thereby enabling oncologists to act quickly and with greater certainty.

Roche’s navify platform will be used to develop integrated algorithms that can detect biomarkers and predict patient responses to certain treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initially focusing on NSCLC, the partnership plans to expand these progressions to other tumours and diseases in the future.

It leverages Sheba’s digital pathology expertise and the clinical decision support capabilities of Roche, underscoring a joint dedication to enhancing personalised medicine.

Sheba Medical Center director-general Prof Yitshak Kreiss said: “This collaboration marks an exciting moment in our efforts to transform healthcare on a global scale. When one of the world’s leading digital pathology providers teams up with Sheba’s leading innovators in AI-driven diagnostics, it’s not just a statement of intent; it’s the start of a groundbreaking journey.

“Together, we will be able to advance patient care in ways that were previously unimaginable. This collaboration will help us leverage advanced technologies to create new benchmarks for diagnostic accuracy and treatment efficacy.”

Recently, Roche secured CE mark approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, for the identification of epithelial ovarian cancer (EOC) individuals suitable for targeted therapy with AbbVie’s ELAHERE (mirvetuximab soravtansine).